402 related articles for article (PubMed ID: 21931292)
1. Expansion of human peripheral blood γδ T cells using zoledronate.
Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
[TBL] [Abstract][Full Text] [Related]
2. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
[TBL] [Abstract][Full Text] [Related]
3. Butyrophilin 3A/CD277-Dependent Activation of Human γδ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations.
Nerdal PT; Peters C; Oberg HH; Zlatev H; Lettau M; Quabius ES; Sousa S; Gonnermann D; Auriola S; Olive D; Määttä J; Janssen O; Kabelitz D
J Immunol; 2016 Oct; 197(8):3059-3068. PubMed ID: 27619996
[TBL] [Abstract][Full Text] [Related]
4. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.
Roelofs AJ; Jauhiainen M; Mönkkönen H; Rogers MJ; Mönkkönen J; Thompson K
Br J Haematol; 2009 Jan; 144(2):245-50. PubMed ID: 19016713
[TBL] [Abstract][Full Text] [Related]
6. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
[TBL] [Abstract][Full Text] [Related]
7. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
8. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes.
Nussbaumer O; Gruenbacher G; Gander H; Thurnher M
Blood; 2011 Sep; 118(10):2743-51. PubMed ID: 21673342
[TBL] [Abstract][Full Text] [Related]
9. Small molecules for the activation of human gammadelta T cell responses against infection.
Kabelitz D
Recent Pat Antiinfect Drug Discov; 2008 Jan; 3(1):1-9. PubMed ID: 18221182
[TBL] [Abstract][Full Text] [Related]
10. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model.
Sicard H; Ingoure S; Luciani B; Serraz C; Fournié JJ; Bonneville M; Tiollier J; Romagné F
J Immunol; 2005 Oct; 175(8):5471-80. PubMed ID: 16210655
[TBL] [Abstract][Full Text] [Related]
11. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
12. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells.
Li J; Herold MJ; Kimmel B; Müller I; Rincon-Orozco B; Kunzmann V; Herrmann T
J Immunol; 2009 Jun; 182(12):8118-24. PubMed ID: 19494338
[TBL] [Abstract][Full Text] [Related]
13. Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism.
Wang H; Sarikonda G; Puan KJ; Tanaka Y; Feng J; Giner JL; Cao R; Mönkkönen J; Oldfield E; Morita CT
J Immunol; 2011 Nov; 187(10):5099-113. PubMed ID: 22013129
[TBL] [Abstract][Full Text] [Related]
14. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
Dhar S; Chiplunkar SV
Cancer Immun; 2010 Nov; 10():10. PubMed ID: 21069948
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells.
Arkko S; Zlatev HP; Mönkkönen H; Räikkönen J; Benzaïd I; Clézardin P; Mönkkönen J; Määttä JA
Cancer Lett; 2015 Feb; 357(1):279-285. PubMed ID: 25444923
[TBL] [Abstract][Full Text] [Related]
16. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
17. Anti-fibrotic characteristics of Vγ9+ γδ T cells in systemic sclerosis.
Markovits N; Bendersky A; Loebstein R; Brusel M; Kessler E; Bank I
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):23-29. PubMed ID: 26886502
[TBL] [Abstract][Full Text] [Related]
18. Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
Nada MH; Wang H; Workalemahu G; Tanaka Y; Morita CT
J Immunother Cancer; 2017; 5():9. PubMed ID: 28239463
[TBL] [Abstract][Full Text] [Related]
19. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.
Fiore F; Castella B; Nuschak B; Bertieri R; Mariani S; Bruno B; Pantaleoni F; Foglietta M; Boccadoro M; Massaia M
Blood; 2007 Aug; 110(3):921-7. PubMed ID: 17403919
[TBL] [Abstract][Full Text] [Related]
20. Targeting gamma delta T cells for cancer immunotherapy: bench to bedside.
Gogoi D; Chiplunkar SV
Indian J Med Res; 2013 Nov; 138(5):755-61. PubMed ID: 24434328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
